Skip to main content
. 2019 Sep 24;1(1):41–50. doi: 10.1016/j.jaccao.2019.08.014

Table 2.

Age-Adjusted and Multivariable-Adjusted Hazard Ratios of Cardiovascular Events According to Categories of Pre-Diagnosis Exercise (MET h/week)

Total (N = 4,015) MET h/week
p Value for Trend
<2.50 (n = 994) 2.50 to <8.625 (n = 1,008) 8.625 to <18.00 (n = 1,011) ≥18.00 (n = 1,002)
Median MET h/week 8.67 0.0 5.25 13.00 26.33
Cardiovascular events
 No. of events (annualized %) 342 (1.14) 103 88 86 65
 Age-adjusted HR (95% CI) Ref. 0.77 (0.58–1.03) 0.75 (0.56–0.99) 0.59 (0.43–0.80) 0.001
 Multivariable-adjusted HR (95% CI) Ref. 0.80 (0.59–1.09) 0.86 (0.64–1.17) 0.63 (0.45–0.88) 0.016
MI
 No. of events (annualized %) 89 (0.29) 25 22 24 18
 Age-adjusted HR (95% CI) Ref. 0.79 (0.45–1.40) 0.84 (0.48–1.48) 0.67 (0.37–1.24) 0.262
 Multivariable-adjusted HR (95% CI) Ref. 0.83 (0.44–1.53) 1.05 (0.57–1.92) 0.68 (0.34–1.36) 0.373
Heart failure
 No. of events (annualized %) 49 (0.16) 18 11 12 8
 Age-adjusted HR (95% CI) Ref. 0.58 (0.27–1.22) 0.63 (0.30–1.31) 0.43 (0.19–1.00) 0.075
 Multivariable-adjusted HR (95% CI) Ref. 0.64 (0.29–1.43) 0.94 (0.43–2.04) 0.57 (0.23–1.44) 0.366
Cardiovascular death
 No. of events (annualized %) 215 (0.44) 69 54 45 47
 Age-adjusted HR (95% CI) Ref. 0.68 (0.47–0.98) 0.56 (0.38–0.82) 0.62 (0.43–0.90) 0.022
 Multivariable-adjusted HR (95% CI) Ref. 0.73 (0.50–1.06) 0.60 (0.40–0.90) 0.69 (0.46–1.04) 0.109
CHD death (annualized %)
 No. of events 96 (0.22) 36 25 19 16
 Age-adjusted HR (95% CI) Ref. 0.59 (0.36–0.99) 0.45 (0.26–0.79) 0.40 (0.22–0.72) 0.003
 Multivariable-adjusted HR (95% CI) Ref. 0.65 (0.38–1.10) 0.46 (0.25–0.83) 0.41 (0.21–0.78) 0.006

Annualized percentage is the total number with the event divided by the total person-years for all women at risk for the event.

CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; MET = metabolic equivalent task; MI = myocardial infarction; WHI = Women’s Health Initiative.

Cardiovascular events include heart failure, myocardial infarction, angina, coronary revascularization, peripheral artery disease, carotid artery disease, transient ischemic attack, stroke, and cardiovascular death.

Follow-up through September 30, 2010. Adjusted for age at WHI enrollment (continuous), race (white, black, Hispanic, other), smoking status (never, past, current), body mass index (<25, 25 to <30, ≥30 kg/m2), stage (localized, regional), education (less than high school, high school diploma/GED, school after high school, college degree or higher), study (HT randomized; DM randomized, not in HT; OS enrolled), hormone therapy/trial arm (non-user, estrogen-alone, estrogen + progestin), family history of MI, and comorbidities index (count of diabetes, hypertension, treated hypercholesterolemia, history of chronic obstructive pulmonary disease (COPD), lupus/rheumatoid arthritis, history of liver disease, history of stomach ulcer). Models are stratified by age at diagnosis (50 to 59, 60 to 64, 65 to 69, 70 to 74, ≥75 years) and extension study participation (yes/no), allowing the baseline hazards to vary in these strata.

Deaths as of September 30, 2015, including from NDI searches. Adjusted for age at WHI enrollment (continuous), race (white, black, Hispanic, other), smoking status (never, past, current), body mass index (<25, 25 to <30, ≥30 kg/m2), stage (localized, regional), education (less than high school, high school diploma/GED, school after high school, college degree or higher), study (HT randomized; DM randomized, not in HT; OS enrolled), hormone therapy/trial arm (nonuser, estrogen-alone, estrogen + progestin), family history of MI, and comorbidities index (count of diabetes, hypertension, treated hypercholesterolemia, history of COPD, lupus/rheumatoid arthritis, history of liver disease, history of stomach ulcer). Models are stratified by age at diagnosis (50 to 59, 60 to 64, 65 to 69, 70 to 74, ≥75 years).